Table of Contents
Peter Davies, MD, PhD, appointed first provost for UTHealth
In January 2010, Peter Davies, MD, PhD, was appointed the first provost at The University of Texas Health Science Center at Houston (UTHealth).
Larry R. Kaiser, MD, president of UTHealth, made the announcement, saying “Dr. Davies is uniquely qualified through his depth of knowledge of this institution to facilitate the interactions of our six schools and institutes and centers. With his leadership, I know we will see increasing collaborative endeavors among the university’s components as we pursue a common agenda of excellence and service. We are most fortunate that Dr. Davies has accepted this critical position.”
In addition to serving as provost, Davies continues his role as executive vice president for research. His primary responsibilities are to foster the growth of the university’s research and educational enterprise and serve as chief administrator of central academic departments and services from accreditation to strategic academic investments. He also leads initiatives to promote faculty development, enhance educational programs in the schools, recruit and retain faculty and students, develop broad community and outreach academic service, and support a richly diverse university community.
Upon the announcement, Davies said, “I am delighted with this opportunity. Having spent more than 30 years at the university, I have had a chance to see it grow and mature into a fine institution where exceptionally talented people work together to advance health education and research in the community. I look forward to working with the leadership as we continue to connect education and research in bold, innovative ways.”
Davies, a professor of integrative biology and pharmacology at UTHealth Medical School, is a physician-scientist with a longstanding research focus on the molecular biology and pharmacology of the Retinoid X Receptor, which when activated by certain drugs, has shown favorable effects on diabetes and certain cancers.
He earned his MD in 1972 and his doctorate in biochemistry in 1975 from the University of Miami Medical School, and then spent four years at the National Cancer Institute of the National Institutes of Health. In 1979, he joined the Department of Pharmacology at UTHealth Medical School. He also was one of the founders of the medical school’s MD/PhD program and served as its leader for 10 years.
Meredith Raine, Office of Advancement